A new combination of Factor Xa inhibition and standard antiplatelet therapy to prevent more recurrent cardiovascular events after ACS

With an unrestricted educational grant from BAYER HEALTHCARE PHARMACEUTICALS

Learning Objectives

  • To understand the dual pathway approach in arterial thrombus formation and the role of thrombin in platelet activation and aggretation, and in the coagulation cascade
  • To comprehend the increased thrombin generation after ACS and the rationale for oral antiplatelet and anticoagulant therapy to reduce residual atherothrombotic risk for patients following ACS
  • To assess how the use of oral anticoagulation may change current standards of care in patients experiencing ACS with elevated cardiac biomarker